1. Home
  2. RIGL vs BBNX Comparison

RIGL vs BBNX Comparison

Compare RIGL & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

N/A

Current Price

$39.76

Market Cap

911.8M

Sector

Health Care

ML Signal

N/A

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

N/A

Current Price

$13.40

Market Cap

897.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RIGL
BBNX
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
911.8M
897.6M
IPO Year
2000
2025

Fundamental Metrics

Financial Performance
Metric
RIGL
BBNX
Price
$39.76
$13.40
Analyst Decision
Buy
Buy
Analyst Count
4
15
Target Price
★ $64.40
$25.10
AVG Volume (30 Days)
204.0K
★ 1.0M
Earning Date
11-05-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1867.68
78.95
EPS
★ 1.97
N/A
Revenue
★ $294,282,000.00
$100,251,000.00
Revenue This Year
$5.32
$25.25
Revenue Next Year
$24.14
$47.07
P/E Ratio
$21.00
★ N/A
Revenue Growth
★ 64.15
53.94
52 Week Low
$24.84
$8.80
52 Week High
$52.61
$32.71

Technical Indicators

Market Signals
Indicator
RIGL
BBNX
Relative Strength Index (RSI) 34.58 35.12
Support Level $37.60 $12.36
Resistance Level $43.74 $15.00
Average True Range (ATR) 2.72 1.51
MACD -0.62 -0.30
Stochastic Oscillator 15.98 9.62

Price Performance

Historical Comparison
RIGL
BBNX

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Share on Social Networks: